POLL: Which September FDA Approval Are You Looking Forward To?

Click here to answer this week's poll.

Which September FDA Approval Are You Looking Forward To?

Revance's daxibotulinumtoxinA for glabbelar lines; PDUFA September 8, 2022
Bristol Myers Squibb's deucravacitinib for psoriasis; PDUFA September 10, 2022
Sanofi/Regneron's dupilumab for prurigo nodularis; PDUFA September 30, 2022
Related Content

POLL: What is Your Current Approach to Peanut Allergies in Your Atopic Dermatitis Patients?

March 21st 2023

POLL: What Will Catch Your Eye In The AAD Exhibit Hall?

March 15th 2023

POLL: What Are You Most Looking Forward to at AAD 2023?

March 14th 2023

POLL: Are You Attending AAD 2023?

March 13th 2023

POLL: What is a Precursor to Squamous Cell Carcinoma?

March 6th 2023

POLL: What is the Most Common Type of Mole Found on Adults?

February 27th 2023

POLL: What is Your Current Approach to Peanut Allergies in Your Atopic Dermatitis Patients?

March 21st 2023

POLL: What Will Catch Your Eye In The AAD Exhibit Hall?

March 15th 2023

POLL: What Are You Most Looking Forward to at AAD 2023?

March 14th 2023

POLL: Are You Attending AAD 2023?

March 13th 2023

POLL: What is a Precursor to Squamous Cell Carcinoma?

March 6th 2023

POLL: What is the Most Common Type of Mole Found on Adults?

February 27th 2023

POLL: What is Your Current Approach to Peanut Allergies in Your Atopic Dermatitis Patients?

March 21st 2023

POLL: What Will Catch Your Eye In The AAD Exhibit Hall?

March 15th 2023

POLL: What Are You Most Looking Forward to at AAD 2023?

March 14th 2023

POLL: Are You Attending AAD 2023?

March 13th 2023

POLL: What is a Precursor to Squamous Cell Carcinoma?

March 6th 2023

POLL: What is the Most Common Type of Mole Found on Adults?

February 27th 2023
© 2023 MJH Life Sciences

All rights reserved.